Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 55

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 55
---
 (17,447.85)
  
    Financing Activities 
     1,696,899  
     1,903,291  
     (206,392) 
     (10.84)
  
    Effect of Foreign Currency Translation on Cash Flow 
     (9,904) 
     (824) 
     (9,080) 
     1,101.94 
  
    Net Increase in Cash and Cash Equivalents 
    $1,792,147  
    $752,215  
    $1,039,932  
     138.25%

31

Cash Used in Operating Activities

Net cash used in operating activities was $1,597,366 for the three
months ended March 31, 2025, as compared to $1,140,438 for the three months ended March 31, 2024. Our net cash used in operating activities
increased, primarily due to higher general and administrative expenses at $1,686,264 for the three months ended March 31, 2025 ($1,075,134
for the three months ended March 31, 2024), as a result of higher sales, advertising and promotion costs and investor outreach expenses,
as discussed above. In addition, we incurred higher research and development costs at $407,622 for the three months ended March 31, 2025
($337,182 for the three months ended March 31, 2024), primarily related to conducting our tafenoquine-babesiosis trial.

Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was
$1,702,518 for the three months ended March 31, 2025, as compared to net cash used in investing activities of $9,814 for the three months
ended March 31, 2024. For the three months ended March 31, 2025, we received proceeds of $1,708,000 from maturities of certain short-term
investments in certificates of deposit ($0 for the three months ended March 31, 2024). The cash proceeds are partially offset by higher
capitalized patent costs of $2,804 and fixed asset purchases of $2,678 for the three months ended March 31, 2025 ($726 and $0 for the
three months ended March 31, 2024, respectively). However, we did not capitalize website development costs